Holen Sie sich die Stockscreener-App
134.06
3.11%
-4.165
Handel nachbörslich:
134.50
0.435
+0.32%
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC) - Kavout
Celcuity Inc. Advances SEC Compliance and Capital Markets Goals - Faegre Drinker Biddle & Reath LLP
Price-Driven Insight from (CELC) for Rule-Based Strategy - Stock Traders Daily
Celcuity Inc. Files Amendment No. 1 to Form 8-K/A with SEC for February 2026 Event - Minichart
Celcuity Inc. Appoints Charles Romp to Compensation Committee and Nominating and Corporate Governance Committee, Effective May 14, 2026 - marketscreener.com
Celcuity’s Gedatolisib Shines Amid Mounting Cash Burn - TipRanks
Celcuity Is Maintained at Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $185 - Moomoo
Celcuity Shareholders Approve New 2026 Equity Incentive Plans - The Globe and Mail
Celcuity: Approaching An Inflection Point With Gedatolisib (NASDAQ:CELC) - Seeking Alpha
CELC Maintained by HC Wainwright & Co. -- Price Target Raised to $185 - GuruFocus
Citizens reiterates Celcuity stock rating ahead of July approval By Investing.com - Investing.com Australia
Celcuity (CELC) price target increased by 20.06% to 159.86 - MSN
Citizens reiterates Celcuity stock rating ahead of July approval - Investing.com UK
Celcuity stock price target raised to $185 by H.C. Wainwright - Investing.com UK
Celcuity stock price target raised to $185 by H.C. Wainwright By Investing.com - Investing.com Australia
UBS Group AG Reduces Stock Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity Price Target Raised to $185.00/Share From $165.00 by HC Wainwright & Co. - Moomoo
Why Celcuity (CELC) Is Up 5.1% After VIKTORIA-1 Success And Pipeline ExpansionAnd What's Next - Sahm
Celcuity outlines VIKTORIA-2 expansion while targeting July 17 FDA decision for gedatolisib - MSN
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst - Sahm
Celcuity (CELC) Gets a Buy from Stifel Nicolaus - The Globe and Mail
Celcuity Inc. (NASDAQ:CELC) Q1 2026 Earnings Call Transcript - Insider Monkey
Assessing Celcuity (CELC) Valuation After Positive VIKTORIA 1 Data And Upcoming FDA Decision - Yahoo Finance
Celcuity Q1 earnings call highlights - MSN
Celcuity’s Earnings Call: Strong Data, Rising Cash Burn - TipRanks
Celcuity (NASDAQ:CELC) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Stifel raises Celcuity stock price target on trial expansion potential - Investing.com UK
Celcuity's cancer drug expansion could ignite massive new market opportunity: Analyst - MSN
Analysts Are Bullish on Top Healthcare Stocks: Celcuity (CELC), Rubicon Organics (ROMJF) - The Globe and Mail
What's Going On With Celcuity Stock Friday?Celcuity (NASDAQ:CELC) - Benzinga
Stifel raises Celcuity stock price target on trial expansion potential By Investing.com - Investing.com Australia
Stifel Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $175 - Moomoo
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $157 to $183 - Moomoo
Celcuity Inc. Stock 12‑Month Price Target Raised to $167.18, Implies 24% Upside - TradingView
Celcuity Inc. Stock 12‑Month Price Target Raised to $164, Implies 22% Upside - TradingView
Celcuity Inc. Stock 12‑Month Price Target Raised to $159, Implies 18% Upside - TradingView
Celcuity Q1 2026 Earnings Call Transcript - MarketBeat
Celcuity Q1 Earnings Call Highlights - sharewise.com
CELC: Positive phase III data and commercial launch readiness mark a pivotal Q1 2026 - TradingView
Celcuity (CELC) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Celcuity’s Q1 2026 results beat expectations - Investing.com
Earnings call transcript: Celcuity’s Q1 2026 results beat expectations By Investing.com - Investing.com Canada
Transcript: Celcuity Q1 2026 Earnings Conference Call - Benzinga
Celcuity Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Celcuity Inc. (NASDAQ:CELC) Q1 Earnings Beat Forecasts, But Stock Drops on Phase 3 Data Focus - ChartMill
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):